title: Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study.
abstract: PUFA from fish oil appear to have anti-inflammatory and anti-oxidative effects and improve nutritional status in cancer patients. With this as background, the aim of the present study was to investigate the effect of EPA plus DHA on inflammatory condition, and oxidative and nutritional status in patients with lung cancer. In our multicentre, randomised, double-blind trial, thirty-three patients with a diagnosis of advanced inoperable non-small-cell lung cancer and undergoing chemotherapy were divided into two groups, receiving four capsules/d containing 510 mg of EPA and 340 mg of DHA, or 850 mg of placebo, for 66 d. At the start of chemotherapy (T₀), after 8 d (T₁), 22 d (T₂) and 66 d (T₃), biochemical (inflammatory and oxidative status parameters) and anthropometric parameters were measured in both groups. A significant increase of body weight in the n-3 group at T₃ v. T₀ was observed. Concerning inflammation, C-reactive protein and IL-6 levels differed significantly between the n-3 and placebo groups at T₃, and progressively decreased during chemotherapy in the n-3 group, evidencing n-3 PUFA anti-inflammatory action. Concerning oxidative status, plasma reactive oxygen species levels increased in the placebo group v. the n-3 group at the later treatment times. Hydroxynonenal levels increased in the placebo group during the study, while they stabilised in the n-3 group. Our data confirm that the continual assumption of EPA plus DHA determined an anti-inflammatory and anti-oxidative action which could be considered a preliminary goal in anti-cachectic therapy.
authors: Department of Clinical Nutrition, San Giovanni Battista Hospital, Turin, Italy. cfinocchiaro@molinette.piemonte.it
authors: Concetta
authors: C
authors: Finocchiaro
authors: Olivia
authors: O
authors: Segre
authors: Maurizio
authors: M
authors: Fadda
authors: Taira
authors: T
authors: Monge
authors: Mara
authors: M
authors: Scigliano
authors: Marina
authors: M
authors: Schena
authors: Marco
authors: M
authors: Tinivella
authors: Elisa
authors: E
authors: Tiozzo
authors: Maria G
authors: MG
authors: Catalano
authors: Mariateresa
authors: M
authors: Pugliese
authors: Nicoletta
authors: N
authors: Fortunati
authors: Manuela
authors: M
authors: Aragno
authors: Giuliana
authors: G
authors: Muzio
authors: Marina
authors: M
authors: Maggiora
authors: Manuela
authors: M
authors: Oraldi
authors: Rosa A
authors: RA
authors: Canuto
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000178:diet therapy* / Q000188:drug therapy / Q000276:immunology; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D019587:Dietary Supplements / Q000009:adverse effects; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000178:diet therapy* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D018384:Oxidative Stress; D010352:Patient Dropouts; D015430:Weight Gain; D000093542:Gemcitabine
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D000975:Antioxidants; D015525:Fatty Acids, Omega-3; C508600:IL6 protein, human; D015850:Interleukin-6; D003841:Deoxycytidine; D004281:Docosahexaenoic Acids; D002097:C-Reactive Protein; D015118:Eicosapentaenoic Acid; D002945:Cisplatin; D000093542:Gemcitabine